Jeffery Smith

*** ****** ****, ****** ** *****

919-***-****

ac2s8s@r.postjobfree.com

www.linkedin.com/pub/jeffery-smith/19/A04/999/

CORE COMPETENCIES

Assay development, automation, validation and transfer.

Molecular biology, virology, tissue culture and protein analysis.

BSL2 experience including virus vector systems, mouse inoculation and surgery.

GMP/GLP Requirements

Have helped write, SOPs, patents, scientific posters and papers, Government reports and grants.

PROFESSIONAL EXPERIENCE

Icagen Labs 11/2016 to 9/2017

Contract through Advanced Recruiting Partners (6 Month)

4222 Emperor Blvd # 350, Durham, NC 27703 919-***-****

Assumed the running of a medium throughput lab at a CRO specializing in ion channels. Duties involved florescence assay development and screening as well as radioactive ion flux assays.

Worked closely with molecular biology to screen newly created clones to expand capabilities.

Spearheaded a major library screen vs. the only known HTS assay for NaV 1.9.

UNC Genetics department Dr. Heise 10/2015 to 11/2016

Research assistant

9039 Burnett-Womack, UNC, Chapel Hill 27514 919-***-****

Managed the ORFeome project core lab. This involved molecular, biochemical and lab animal handling to produce antibodies from ORF consensus sequences. Plasmids were cloned and transfected into tissue culture to test expression via western blotting. Those that expressed were then processed through RNA electroporation to create replicons in order to produce antiserum. Deliverables were dispensed to five collaborating labs involved with this 20 million dollar project.

Alera Labs and Drug and Device Development Solutions 7/2015 to 10/2015

HTS Consultant / Formulation assistant

Building 3, 104 TW Alexander Dr, Research Triangle Park, NC 27709 703-***-****

Provide automation, chemistry, and other expertise for two closely associated startups in RTP. Major responsibility was assisting with formulation work, including testing viscosities, preparing formulas, running stability studies and HPLC analysis of analyte and impurities.

Catalent Pharmaceuticals 7/2014 to 10/2014

Contract through Lab Support

160 Pharma Drive, Morrisville, NC 27560 919-***-****

Performed raw product and release testing for a contract pharmaceutical company.

Full-Time Caregiver and Clegg’s Termite & Pest Control 7/2011 to 3/2014

Pesticide applicator

2401 Reichard St, Durham, NC 27705 919-***-****

Provided care for seriously ill family member, including medication management, assistance with activities of daily living, coordinating doctor, hospital and physical therapy visits.

Perform pest management duties for a large, privately owned pest control company.

GLAXOSMITHKLINE – Durham, NC 06/2001 to 7/2011

4117 Emperor Blvd, Durham, NC 27703 Supervisor Gary K Smith 919-***-****

At GSK I worked for and with the same people under several organizational charts. The focus of the department was always early drug discovery in a semi-high-throughput environment. We developed or transferred automated assays using various platforms all under strict QC and GLP conditions. My role grew appropriately with my experience level.

Senior Scientist at GSK (11/2009 to 7/2011)

Developed screening and Mode of Action (MOA) assays to support a 300-employee virology department.

As an extrovert adept at public speaking, I was chosen to spearhead new department interactions in response to virology group restructuring. Educated researchers on department capabilities, identified specific program needs, and increased knowledge and acceptance of our capabilities. Activities improved departmental relations and utilization of services by virology programs.

Performed data analysis and troubleshooting to profile lead molecules and candidates for clinical trials.

Earned Excellence in Science award (2010) for leading method development and method validation effort to transfer the first pseudo-HIV Biological Safety Level 2 (BSL2) assay. This was vital to the virology department and was used by several programs in the HIV virology group. This group of assays provided consistent data and was adopted by other program teams. This effort included completing all necessary company and FDA safety compliance documentation.

Independently, created a kinetic assay documenting tight binding by a select series of compounds containing boron, leading to a reprioritization for the program and eventually to a successful clinical molecule.

Scientist at GSK (11/2007 to 11/2009)

Continued assay work for newly formed department and expanded from kinase assays to other protein assays as well as cell-based and kinetic mode of action studies. I quickly gave up leading by number of wells screened and instead was a leader in number of different assays ran monthly to align with new department goals.

As part of a team I developed and validated modified ELISA assays supporting research in virology, cancer, obesity and anemia, contributing significantly to the discovery of four molecules (2003-2011) that reached human clinical trials, one of which (Hepatitis C) has achieved proof-of-concept.

Created high-throughput assays to elucidate program SAR using new technologies, reducing radiation usage and driving cost per well below 7 cents by investigating and incorporating IMAP bead technology. Performed lab testing, assay optimization, method validation and data analysis as well as assisted with writing of technical reports.

Recognized with monetary Award for contributing to the development and implementation of a successful team oriented vacation coverage strategy vital for the operation of the department.

Assistant Scientist at GSK (7/2002 to 8/2007)

Consistently led department of up to 60 employees in number of successful wells screened and assays run.

Transitioned plate handling interdepartmentally and expanded development and assay work.

Developed enzymatic assays (modified ELISA assays) with various detection methods.

Took over execution of the nuclear receptor assays (a modified ELISA assay) to showcase a broadened SCP-RTP assay range, which included HPLC, GC-Mass Spectroscopy, FP, ELISA, primary cell and tissue culture assays, radiolabelled assays, and luminescence. Thus allowing the department to change focus and increase the number and types of assays performed at RTP.

Earned a Bronze departmental award for effective analysis of data that helped identify a program that should be terminated before commitment to clinical trials, saving millions of dollars.

Used UV/VIS weekly for the identification and confirmation of active drug particles in micro-titer plates to reduce false negative results across all departmental assays.

Automation Specialist at GSK for manpower (6/2001 to 7/2002)

Used automation expertise to create assay-ready plates to support ADCP Kinase activities.

Converted department standard format from a 96-well to 384-well operation, which increased capacity and reduced operating costs.

Earned monetary award for facilitating the effort to transfer plate creation activity to compound-handling group to eliminate duplicate plate development efforts.

Maintained weekly and bespoke plate propagation, documented statistical parameters and quickly learned, validated, tested, programmed and switched new equipment through four different procedures.

ANALYTICAL/RESEARCH SKILLS

Assays: Chemistry, biology, biochemistry, virology, immunology, developmental biology, pathogenesis, microbiology, lab management, and ordering. I am experienced in assay development, assay method validation, assay transfer and troubleshooting; skilled with enzymatic assays, including kinases, nuclear receptors, ion channels and replicon based assays; proficient with tissue culture and cell culture using frozen cell assay techniques and fresh cell BSL2 assays. Have used Elisa, modified Elisa, rtPCR, IMAP, HTRF, FRET, luminescence, FP, radionuclide, and kinetic assay detection methods. Have studied flow cytometry, high throughput sequencing, alphascreen luminex assays.

Instrumentation: Proficient with most lab equipment, liquid handlers and lab automation technologies, including Zymark Rapid Plate, beckman Rail Systems, Tecan, CCS Packard, Topcount and Platetrak, Tomtec Quadra, Beckman core systems, Biomek FX and multimek, Wallac Victor and Viewlux, Agilent bioanalyzer, Molecular Devices FLIPR, tetra, Eppendorf, LJL acquest, Waters and Agilent HPLC, GC, and dissolution, NMR, mass spectroscopy, and chromatography/DNA gels electrophoresis.

Techniques: Ability to work independently and as part of a team, excellent record keeping skills and attention to detail. Protein purification using physical separations, HPLC and Column chromatography, western blot analysis, in both SDS and native acrylamide gel electrophoresis. Cellular and molecular biology skills, including cell culture, cloning, virology, replicon production and use, DNA/RNA purification, maxi preps, mini preps, creation, characterization and hybridization of antibodies. Biochemical assays, cell based assays, ELISA, Bradford and structure/function analysis. Cloning, PCR, agarose, Native and PAGE gels. Murine, guinea pig, mouse and rat animal husbandry including necropsy, harvest, making antiserum and collecting blood. I also have wet chemistry and quality control experience. I have method creation, method validation, and method transfer experience. Experience with pleuripotent stem cells. Experience with western, northern and southern blotting.

Software: Robofit, Barcode Buddy, ActivityBase (ABase), Microsoft Office, Chemdraw, Statistica, JMP, turbochrome, elab notebook and proprietary software systems; database management skills; basic skills in most robotic system programming languages, scratch and Visual Basic. I have set up and maintained a website for charity I headed, including a donation page.

EDUCATION AND TRAINING

Master of Science in Biochemistry and Molecular Biology

TEXAS A&M UNIVERSITY

College Station, Texas 77843

Bachelor of Science in Chemistry,

NORTHERN KENTUCKY UNIVERSITY

Highland Heights, Kentucky 41099

PUBLICATIONS

“Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity,” Bioorganic and Medicinal Chemistry Letters. 2009 V19 (2), 360-4. Chamberlain SD, Redman AM, Wilson JW, Deanda F, Shotwell JB, Gerding R, Lei H, Yang B, Stevens KL, Hassell AM, Shewchuk LM, Leesnitzer MA, Smith JL, Sabbatini P, Atkins C, Groy A, Rowand JL, Kumar R, Mook RA Jr, Moorthy G, and Patnaik S.

“Imidazo[5,1-f][1,2,4]triazin-2-amines as novel inhibitors of polo-like kinase 1,” Bioorganic and Medicinal Chemistry Letters. 2008 V18 (23), 6214-7. Cheung M, Kuntz KW, Pobanz M, Salovich JM, Wilson BJ, Andrews CW 3rd, Shewchuk LM, Epperly AH, Hassler DF, Leesnitzer MA, Smith JL, Smith GK, Lansing TJ, and Mook RA Jr.

“N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3,” Bioorganic and Medicinal Chemistry Letters. 2007 V17 (5), 1296–1301. Angell RM, Atkinson FL, Brown MJ, Chuang TT, Christopher JA, Cichy-Knight M, Dunn AK, Hightower KE, Malkakorpi S, Musgrave JR, Neu M, Rowland P, Shea RL, Smith JL, Somers DO, Thomas SA, Thompson G, and Wang R.

“4-Acylamino-6-arylfuro[2,3-d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitors,” Bioorganic and Medicinal Chemistry Letters. 2004 V14 (15), 3907-11. Maeda Y, Nakano M, Sato H, Miyazaki Y, Schweiker SL, Smith JL, and Truesdale AT.

“Dominance in Lambda S mutations and evidence for translational control,” Journal of Molecular Biology. 1987 V199, 95-105 Raab S, Neal S, Sohaskey C, Smith JL, and Young RY.

Contact this candidate